In the Oxford Journal of Gerontology Series A: Biological Sciences and Medical Sciences, the popular nonsteroidal SARM LGD 4033 (Ligandrol) has been recently studied for it’s effectiveness and safety in healthy young men. Results were favorable indicated by hormone and lipid levels returning to normal without the use of a post cycle therapy. No dangers were detected throughout the study. although there was noticeable suppression in testosterone and HDL cholesterol, it was not significant enough to cause adverse reactions. Because LGD 4033 is considered one of the strongest and most potent nonsteroidal SARMs available, it is not likely that less potent SARMs will produce any harmful effects (Bhasin, 2010).